하위메뉴바로가기
본문바로가기
HOME>Company>R&D>R&D History

R&D History

Green Chemicals

After2000

  • Developed a high-heat- and chemical-resistant material for automotive interiors
  • Developed a polyester resin for high-heat-resistant coating (HiPES)
  • Obtained eco-friendly C2C certification for ECOZEN® / SKYGREEN®
  • Developed an eco-friendly, super-engineering PPS plastic material (ECOTRAN®)
  • Obtained FDA FCN certification for the eco-friendly, transparent heat-resistant co-polyester material (ECOZEN®)
  • Developed a high-performance, super-engineering PCT plastic material
  • Developed an eco-friendly, non-BPA toner resin
  • Developed composite parts for fastening insulated panels on LNG carriers
  • Developed a super-capacitor electrolyte
  • Developed a display light absorber model
  • Developed a biodiesel production technology
  • Developed a thermoplastic polyurethane material for breathable films
  • Obtained license for the OAT (organic acid technology) engine coolant technology
  • Developed a high-heat-resistant pre-preg system
  • Developed a liquid photopolymer for flexographic printing plates
  • Developed an organic semiconductor material
  • Developed a TMA (trimellitic anhydride) manufacturing technology
  • Developed a bivalent-metal-free biocide product
  • Developed an eco-friendly, water-soluble OPV (overprint varnish)
  • Developed a new toner binder
  • Developed an eco-friendly, sound-absorbing insulation polyester material
  • Established commercial production technology for CHDM
  • Developed an eco-friendly, high-heat-resistant, and high-performance resin (SKYGREEN) for profile extrusion products

Before1999

  • Developed an industrial disinfectant
  • Developed a PEN resin
  • Developed a biodegradable aliphatic polyester resin
  • Developed a polyester adhesive material
  • Developed a PET resin for bottles

Life Science

After2000

  • Released an immunoglobulin product (Intravenous Hepabulin)
  • Obtained authorization for Korea's first cell-culture influenza vaccine (SKYCellflu®)
  • Applied for authorization of a quadrivalent cell-culture influenza vaccine
  • Developed a next-generation pneumococcal vaccine and entered into supply agreement with Sanofi
  • Released dementia patch in Europe (SID710®)
  • Signed a co-development agreement with the International Vaccine Institute for typhoid conjugate vaccine
  • Released a gastritis medicinal formula (Promac® granules/tablets)
  • Obtained Europe authorization for SID530 (docetaxel injection)
  • Applied for U.S. FDA authorization of NBP601, a recombinant hemophilia treatment
  • Launched Montefree® orally-dissolving film (Montelukast ODF;re-formulated IMD)
  • Launched Mvix-S® orally-dissolving film (Mirodenafil ODF; re-formulated IMD)
  • Released an anticoagulant medicinal formula (Antithrombin®)
  • Launched a hyperlipidemia medicine (Esrotin Tab®)
  • Launched an antithrombotic medicine (Linexin Tab®)
  • Signed an agreement with CSL (Australia) to export NBP601-related technologies (recombinant hemophilia treatment)
  • Launched Korea’s leading natural arthritis medicine (Joins Tab®)
  • Launched a hypertension medicinal formula (Nexad TAb®)
  • Launched hypertension medicine variant (Skad Tab®)
  • Launched a medicinal formula for asthma (Pranair®)
  • Developed and launched a medicinal formula for erectile dysfunction (Mvix Tab®)

Before1999

  • Developed an industrial disinfectant
  • Developed a PEN resin
  • Developed a biodegradable aliphatic polyester resin
  • Developed a polyester adhesive material
  • Developed a PET resin for bottles